

## Pharmaceutical Development of Bio-Molecules

Da-Yong Lu\* and Jin-Yu Che

School of Life Sciences, Shanghai University, Shanghai, China

\*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.

Received: March 09, 2022; Published: March 31, 2022

### Abstract

Biotherapy is increasingly utilized in the clinic. However, most biological agents have shortcomings in clinical applications. Pharmaceutical modifications play key role for drug utilities. This Article gives a brief panorama of pharmaceutical development of bio-agents.

**Keywords:** *Pharmaceutical Modification; Bio-Molecules; Drug Bioavailability; Drug Characteristics*

### Introduction

90% of drugs are chemical agents. They are stable and high-bioavailability in human bodies. However, most chemical drugs can not cure human diseases because they are not real components of human bodies. With the great development of biotechnology, biotherapy is increasingly used in the treatment of different types of human diseases, such as diabetes, cancer, osteoporosis and others in the clinic [1-14]. Correspondingly, biotherapy will be a therapeutic convention in the future.

### Medical problems

Nonetheless, most of biomolecules are short-live in human body. It will cost a lot if we use bio-molecule in its original states. More recently, biomolecules are pharmaceutically modified to stable drug concentrations and avoid immune system targets in human bodies [15].

### Pharmaceutical pathways for biotherapy

So far as we know, this key aspect of pharmaceutical science has a great potentiality. A great variety of new biological drugs may come into the bedside with low toxicity and specificity of drugs.

- Chemically modifying to elongate drug concentrations in patients' blood and tissues
- Stable bio-molecules to avoid immune-attacks from human bodies
- Ligands to nanoparticles that can reduce drug volumes and penetrate to damaged cells or organs
- Peroxisome, liposomes and capsules to deliver biomolecules to disease sites in relatively higher levels [16-23].

### Key characters

Apart from pharmaceutical approaches, several other subjects are associated with bio-drug development and clinical applications:

- Molecular biology
- Pharmacology
- Toxicology
- Clinical therapeutics
- Mathematics.

By integrating these different subjects, bio-agents should be improved greatly.

### Conclusion

Though there is a long way to go for this pharmaceutical development, stabilizing biomolecules and avoiding immune-attacks from human beings. Building biomolecules delivery systems has enormous usefulness in drug development and clinical applications. Present, it is only a beginning.

### Bibliography

1. Lu DY, *et al.* "Diabetes prevention and treatments, a specific topic for modern medicines". *Journal of Metabolic Syndrome* 8.3 (2017): 231.
2. Zimmet PZ, *et al.* "Diabetes; a 21<sup>st</sup> century challenge". *Lancet Diabetes and Endocrinology* 2.1 (2014): 56-64.
3. An Old Disease, A New Insights. Ed, Shamm Ahmad, Springer Science, US (2013).
4. Lu DY. "HIV/AIDS Treatments, Fight for a Cure". LAMBERT Academic Publishing. Ed Da-Yong Lu, Germany (2017).
5. Lu DY, *et al.* "The pathogenesis and treatments of diabetes, questions and answers". *Cell and Developmental Biology* 3.3 (2014): e126.
6. Serafini G., *et al.* "Suicidal ideation: a comprehensive overview". Suicidal Ideation: Predictors, Prevalence and Prevention. Ed. Bradley Weaver. Nova Science Publishing. US, Chapter 1 (2015): 1-42.
7. McAllister-Williams R and Ferrer IN. "Pharmacological management of unipolar affective disorder". *Psychiatry* 8.4 (2009): 113-119.
8. Lu DY, *et al.* "Pathology and treatments of obesity". *Trends in Medicine* 8.5 (2018): 157.
9. Lu DY, *et al.* "Osteoporosis treatments for old people". *EC Orthopedics* 10.5 (2019): 278-280.
10. Lu DY, *et al.* "Biomedical study of human obesity, pathology and counteractive". *Obesity, Open Access* 4.2 (2018): e108.
11. Grimaccia F and Kanavos P. "Cost, outcome, treatment pathways and challenges for diabetes care in Italy". *Global Health* 10.1 (2014): 58.
12. Lu DY, *et al.* "Type 2 diabetes treatment and drug development study". *The Open Diabetes Journal* 8 (2018): 22-33.
13. Lu DY, *et al.* "Human suicide risk and treatment study". *Central Nervous System Agents in Medicinal Chemistry* 18.3 (2018): 206-212.
14. Lu DY, *et al.* "HIV/AIDS curable study, new forms of therapeutic trinity". *Recent Patents on Anti-Infective Drug Discovery* 13.3 (2018): 217-227.

15. Lu DY and Che JY. "Drug delivery of bio-molecules". *EC Pharmacology and Toxicology* 10.2 (2022): 83-85.
16. Rys P, *et al.* "Efficacy and safety comparison of rapid-acting insulin as part and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus; a systematic review". *Diabetes and Metabolism* 37.3 (2011): 190-200.
17. Ashraf GM. "New emerging trends in protein and peptide-based therapeutic approach—Part II". *Current Protein and Peptide Science* 19.9 (2018): 840.
18. Vasudevan V, *et al.* "Post translational modification and its pathologic association in rheumatoid arthritis: a brief prospective". *Current Protein and Peptide Science* 22.7 (2021): 548-558.
19. Reig-Vano B, *et al.* "Alginate-based hydrogels for cancer therapy and research". *International Journal Biological Macromolecules* 170 (2021): 424-436.
20. Sharifi-Rad J, *et al.* "Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment". *Cancer Cell International* 21.1 (2021): 318.
21. Jain V, *et al.* "A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer". *Journal of Controlled Release* 326 (2020): 628-647.
22. Lu DY and Che JY. "Osteoporosis in old women, possible breakthroughs". *Acta Scientific Orthopaedics* 4.11 (2021): 1-3.
23. Xie YJ, *et al.* "Osteoimmunomodulatory effects of biomaterials modification strategies on macrophage polarization and bone regeneration". *Regenerative Biomaterials* 7.3 (2020): 233-245.

**Volume 10 Issue 4 April 2022**

© All rights reserved by Da-Yong Lu and Jin-Yu Che.